AVI avails itself of Jayant Aphale as senior VP
This article was originally published in Scrip
AVI BioPharma, a developer of RNA-based therapeutics, has appointed Dr Jayant Aphale senior vice-president of technical operations, with responsibility for all of AVI's internal and outsourced manufacturing activities. Dr Aphale brings over 18 years of cGMP technical operations and cross-functional leadership experiences, and most recently served as vice-president at GlaxoSmithKline in Belgium leading new product introductions, cGMP scale-up of clinical material manufacturing, US government interactions and global technology transfer of marketed vaccines.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.